NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

BERCOLAGENE TELSERPAVEC (KB103):新興醫藥品的考察、市場預測 (2030年)

BERCOLAGENE TELSERPAVEC (KB103)- Emerging Drug Insight and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 959706
出版日期 按訂單生產 內容資訊 英文 50 Pages
商品交期: 10個工作天內
價格
BERCOLAGENE TELSERPAVEC (KB103):新興醫藥品的考察、市場預測 (2030年) BERCOLAGENE TELSERPAVEC (KB103)- Emerging Drug Insight and Market Forecast - 2030
出版日期: 按訂單生產內容資訊: 英文 50 Pages
簡介

B-VEC是Krystal的主要產品候選產品,其尋求使用基因療法來治療營養不良性表皮鬆解性大皰(DEB),這是一種由於皮膚缺乏膠原蛋白而導致的無法治癒的皮膚起泡現象。B-VEC是一種複製缺陷型,非整合型病毒載體,採用Krystal的STAR-D平台將功能性人COL7A1基因直接遞送至患者的分裂和非分裂皮膚細胞。Krystal的HSV-1是專有載體,與其他病毒載體相比,可以更有效地穿透皮膚細胞。它的高有效負載能力使其可以容納較大或多個基因,其低免疫原性使其成為直接和重複遞送至皮膚的合適選擇。

本報告提供美國,歐洲5個國家(德國,法國,義大利,西班牙,英國)以及日本的7個主要市場上 BERCOLAGENE 關於TELSERPAVEC (KB103) 詳細說明 (含作用機制,劑量,合成途徑,法規的里程碑的研究開發活動,及其他的開發活動),含SWOT分析,市場競爭企業,及其他新治療方法的未來市場評估。

目錄

第1章 醫藥品概要

  • 產品詳細內容
  • 作用機制
  • 投藥和管理
  • 研究開發活動
    • 臨床開發
    • 安全性和有效性
  • 其他開發活動

第2章 市場評估

  • 主要7個國家市場分析
  • 美國市場
  • 德國市場
  • 法國市場
  • 義大利市場
  • 西班牙市場
  • 英國市場
  • 日本市場

第3章 SWOT分析

第4章 分析師的見解

第5章 市場競爭企業

第6章 其他的新治療方法

第7章 附錄

第8章 報告購買選擇

目錄
Product Code: DIDM0057

"BERCOLAGENE TELSERPAVEC (KB103)- Emerging Drug Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Epidermolysis bullosa in 7 Major Markets. A detailed picture of the BERCOLAGENE TELSERPAVEC (KB103) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Drug Summary:

B-VEC is Krystal's lead product candidate that seeks to use gene therapy to treat dystrophic epidermolysis bullosa, or DEB, an incurable skin blistering condition caused by a lack of collagen in the skin. B-VEC is a replication-defective, non-integrating viral vector employing Krystal's STAR-D platform to deliver functional human COL7A1 genes directly to the patients' dividing and non-dividing skin cells. Krystal's HSV-1 is a proprietary vector that can penetrate skin cells more efficiently than other viral vectors. Its high payload capacity allows it to accommodate large or multiple genes and its low immunogenicity makes it a suitable choice for direct and repeat delivery to the skin.

Scope of the report:

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around BERCOLAGENE TELSERPAVEC (KB103).
  • The report contains forecasted sales for BERCOLAGENE TELSERPAVEC (KB103) till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase III) for Epidermolysis bullosa.
  • The report also features the SWOT analysis with analyst insights and key findings of BERCOLAGENE TELSERPAVEC (KB103).

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

BERCOLAGENE TELSERPAVEC (KB103) Analytical Perspective by DelveInsight

  • In-depth BERCOLAGENE TELSERPAVEC (KB103) Market Assessment

This report provides a detailed market assessment of BERCOLAGENE TELSERPAVEC (KB103) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

  • BERCOLAGENE TELSERPAVEC (KB103) Clinical Assessment

The report provides the clinical trials information of BERCOLAGENE TELSERPAVEC (KB103) covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights:

  • In the coming years, the market scenario for Epidermolysis bullosa is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence BERCOLAGENE TELSERPAVEC (KB103) dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for Epidermolysis bullosa are giving market competition to BERCOLAGENE TELSERPAVEC (KB103) and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of BERCOLAGENE TELSERPAVEC (KB103).
  • Our in-depth analysis of the forecasted sales data of BERCOLAGENE TELSERPAVEC (KB103) from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the BERCOLAGENE TELSERPAVEC (KB103).

Key Questions:

  • Which company is developing BERCOLAGENE TELSERPAVEC (KB103) along with the phase of the clinical study?
  • What is the technology utilized in the development of BERCOLAGENE TELSERPAVEC (KB103)?
  • What is the product type, route of administration and mechanism of action of BERCOLAGENE TELSERPAVEC (KB103)?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the BERCOLAGENE TELSERPAVEC (KB103) development?
  • What are the key designations that have been granted to BERCOLAGENE TELSERPAVEC (KB103)?
  • What is the forecasted market scenario of BERCOLAGENE TELSERPAVEC (KB103)?
  • What is the history of BERCOLAGENE TELSERPAVEC (KB103) and what is its future?
  • What is the forecasted sales of BERCOLAGENE TELSERPAVEC (KB103) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how these are giving competition to BERCOLAGENE TELSERPAVEC (KB103)?
  • Which are the late-stage emerging therapies under development for the treatment of the PPD?

Table of Contents

1. Drug Overview

  • 1.1. Product Detail
  • 1.2. Mechanism of Action
  • 1.3. Dosage and Administration
  • 1.4. Research and development activity
    • 1.4.1. Clinical Development
    • 1.4.2. Safety and Efficacy
  • 1.5. Other Development Activities

2. Market Assesment

  • 2.1. 7MM Market Analysis
  • 2.2. The United States Market
  • 2.3. Germany Market
  • 2.4. France Market
  • 2.5. Italy Market
  • 2.6. Spain Market
  • 2.7. United Kingdom Market
  • 2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

8. Report Purchase Options

List of Tables

  • Table 1 BERCOLAGENE TELSERPAVEC (KB103), Description
  • Table 2 BERCOLAGENE TELSERPAVEC (KB103), Clinical Trial Description
  • Table 3 BERCOLAGENE TELSERPAVEC (KB103), 7MM Market Size from 2020 to 2030 (in Million USD)
  • Table 4 Market Competitors
  • Table 5 Other Emerging Therapies

List of Figures

  • Figure 1 The Development Timeline of BERCOLAGENE TELSERPAVEC (KB103)
  • Figure 2 Patent Details, BERCOLAGENE TELSERPAVEC (KB103)
  • Figure 3 BERCOLAGENE TELSERPAVEC (KB103), 7MM Market Size from 2020 to 2030 (in Million USD)
  • Figure 4 BERCOLAGENE TELSERPAVEC (KB103), US Market Size from 2020 to 2030 (in Millions USD)
  • Figure 5 BERCOLAGENE TELSERPAVEC (KB103), EU5 Market Size from 2020 to 2030 (in Millions USD)
  • Figure 6 BERCOLAGENE TELSERPAVEC (KB103), Japan Market Size from 2020 to 2030 (in Millions USD)